We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to ...

BioNTech SE (NASDAQ:BNTX) presented promising new clinical data for its oncology programs, including BNT327 and mRNA cancer immunotherapies, indicating potential advancements in cancer treatment.

German drugmaker BioNTech reported Monday wider net loss in its first quarter with weak revenues. Further, the company ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations. Please go ahead. Thank you. Good morning, and good ...

BIONTECH SE ($BNTX) posted quarterly earnings results on Monday, May 5th. The company reported earnings of -$1.60 per share, beating estimates of -$2.13 by $0.53. The ...

BioNTech SE (NASDAQ:BNTX) presented promising new clinical data for its oncology programs, including BNT327 and mRNA cancer immunotherapies, indicating potential advancements in cancer treatment. The ...

Mainz, Germany, May 5, 2025(Nasdaq: BNTX, "BioNTech" or "the Company") announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on BioNTech SE (BNTX – Research Report). The company’s shares closed yesterday at $104.68.